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Abstract
Background:  The performance of the WHO recommendations for pediatric antiretroviral
treatment (ART) in resource poor settings is insufficiently documented in routine care.
Methods: We compared clinical and immunological criteria in 366 children aged 0 to 12 years in
Kinshasa and evaluated a simple computation to estimate CD4 percent, based on CD4 count, total
white blood cell count and percentage lymphocytes. Kappa (κ) statistic was used to evaluate
eligibility criteria and linear regression to determine trends of CD4 percent, count and total
lymphocyte count (TLC).
Results: Agreement between clinical and immunological eligibility criteria was poor (κ = 0.26).
One third of children clinically eligible for ART were ineligible using immunological criteria; one
third of children immunologically eligible were ineligible using clinical criteria. Among children
presenting in WHO stage I or II, 54 (32%) were eligible according to immunological criteria.
Agreement with CD4 percent was poor for TLC (κ = 0.04), fair for total CD4 count (κ = 0.39)
and substantial for CD4 percent computational estimate (κ = 0.71). Among 5 to 12 years old
children, total CD4 count was higher in younger age groups (-32 cells/mm3 per year older), CD4
percent was similar across age groups.
Conclusion:  Age-specific thresholds for CD4 percent optimally determine pediatric ART
eligibility. The use of CD4 percent computational estimate may increase ART access in settings with
limited access to CD4 percent assays.
Background
To facilitate the rapid scale-up of pediatric antiretroviral
treatment (ART), the World Health Organization (WHO)
published revised pediatric ART guidelines for resource
poor settings in 2006 [1]. The ART eligibility criteria for
infants and children rely on clinical and/or immunologi-
cal thresholds and aim to identify those children with
poor prognosis if ART initiation is delayed.
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The WHO clinical staging system has been widely used in
resource-limited countries, particularly in the African
Region, and has proved pragmatic and useful in facilities
at the primary care and referral level [1]. An evaluation of
the guidelines in Zambia showed 20-fold higher mortality
rates in children with WHO clinical stage IV compared to
stages I and II, confirming the association of clinical stage
with prognosis [2].
Similarly, WHO immunological thresholds for total CD4+
T lymphocyte count (CD4 count) and CD4 percent (Table
1) are associated with prognosis, and correspond to a 5%
annual mortality risk in US and European children aged
one year or older [3]. An identical level of immunosup-
pression in children in resource poor settings may how-
ever not have the same prognostic value due to differences
in genetic and environmental factors such as opportunis-
tic infections or malnutrition [4,5]. For example, CD4 per-
cent and CD4 count in healthy Kenyan children was
markedly lower compared to children from Europe, USA
and West Africa [6]. It is therefore uncertain whether the
use of thresholds established through longitudinal studies
in the US and Europe can be extrapolated to other regions
in the world.
We evaluated the impact of the 2006 WHO pediatric ART
eligibility criteria on ART initiation decision making in a
pediatric HIV care program in Kinshasa, Democratic
Republic of Congo (DRC) and propose a lower cost alter-
native for the expensive CD4 percent assays.
Methods
Study setting
The family-centered "Sustainable AntiRetroviral Access
(SARA)" Program at Kalembe Lembe pediatric hospital in
Kinshasa started in November 2004 and was one of the
first to provide free access to pediatric ART in the DRC.
The program provides prophylaxis and treatment for
opportunistic infections, psychosocial support, nutri-
tional support, insecticide treated bed nets, as well as
antiretroviral treatment, according to national guidelines.
ART eligibility was defined based on the 2004 and 2005
WHO guidelines. Children presenting in WHO stage I or
II were eligible for ART if CD4 percent was below 20% for
children younger than 12 months, below 15% for chil-
dren under the age of 12 years, or if CD4 count was below
200 cells/mm3 for children older than 12 years. Children
presenting at WHO stage III (prior to July 2005) or WHO
stage III/IV (July 2005 to June 2006) were eligible irre-
spective of CD4 percent or CD4 count. First line ART con-
sisted of stavudine, lamivudine and nevirapine for
children weighing more than 15 kilograms and zidovu-
dine, lamivudine and nevirapine for those weighing less.
Study participants and data collection
HIV positive children and children exposed to HIV at
birth were referred to the clinic from the greater Kinshasa
area. All HIV infected children, aged 0 to 18 years that did
not have alternative access to ART, are eligible for the
SARA project. Data on children aged 0 to 12 years enrolled
in the SARA program between November 30, 2004 and
May 30, 2006 were analyzed for this study. Clinical and
laboratory data collected at baseline were analyzed for all
eligible children. Blood samples were collected in the
morning and processed the same day at the National HIV
Reference Laboratory in Kinshasa. CD4 percent and CD4
count were established using the single platform assay
FACSCalibur (Becton Dickinson, Aalst, Belgium). Total
lymphocyte count (TLC) was calculated based on WBC
count and percent lymphocytes as determined by using
the Absorbance Cytochemistry and Volume Technology
5-part differential (ACT 5 diff) hematology analyzer
(Coulter Beckman, VWR international, France).
Data Analysis
For the purpose of this analysis, we evaluated pediatric
ART eligibility using clinical criteria and age-specific
immunological criteria recommended in the 2006 WHO
guidelines for pediatric ART in resource poor settings
(Table 1) [1].
In addition to the CD4 percentage obtained by gold
standard flow cytometry, i.e. FACSCalibur assay, we calcu-
lated the CD4 percent using the following formula: com-
puted CD4 percent = absolute CD4 count/(WBC count ×
percentage lymphocytes). The CD4 count used in this
computation was obtained by flow cytometry.
Fisher's exact test was used to compare proportions and
Kappa (κ) coefficient to assess agreement between ART
eligibility criteria. The κ coefficient was interpreted as fol-
lows: < 0.20: poor agreement, 0.21 – 0.40: fair agreement,
0.41 – 0.60: moderate agreement, 0.61 – 0.80: substantial
agreement, and > 0.80: good agreement [7]. Linear regres-
sion was used to determine trends of CD4 percent, CD4
count and TLC across age groups and correlation between
Table 1: Age-specific ART eligibility criteria for children in 
resource poor settings. Source: World Health Organization: 
Antiretroviral therapy of HIV infection in infants and children in 
resource-limited settings: towards universal access. 
Recommendations for a public health approach, 2006.
Immunological marker Age in months
≤ 11 12 – 35 36 – 59 ≥ 60
CD4 percent* <25% <20% <15% <15%
CD4 count (cells/mm3)* <1500 <750 <350 <200
TLC (cells/mm3)† <4000 <3000 <2500 <2000
* valid for children aged 0 to 12 years; † valid for children aged 0 to 8 
yearsBMC Infectious Diseases 2008, 8:31 http://www.biomedcentral.com/1471-2334/8/31
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CD4 percent measured by flow cytometry and CD4 per-
cent estimate derived through computation. Weight for
age z-score was determined using the 1990 British Grow
Charts references [8]. Malnutrition was defined as a
weight for age z-score of less then minus two. Analyses
were performed using STATA version 9.0 (STATA cooper-
ation, Texas, USA).
Ethical approval
All parents of patients signed informed consent for partic-
ipation, children older than 12 years assented and chil-
dren older than 8 years received an informational sheet
about the study before enrollment. The SARA program
was approved by the Institutional Review Boards of the
University of North Carolina at Chapel Hill, USA, and the
Kinshasa School of Public Health, DRC (IRB reference
number 04-MED-168).
Results
A total of 399 HIV infected, ART-naïve children aged 0 to
12 years, were enrolled in the SARA program between
November 2004 and June 2006. Thirty-three children
were excluded from this analysis because of missing CD4
percent, CD4 count or TLC results at time of enrollment;
leaving 366 (91.7%) children for analysis. The median
age at baseline was 5 years (Interquartile range (IQR): 1.7
to 8.0 years); the median CD4 percent, CD4 count and
TLC by age group are presented in Table 2.
Comparison of clinical and immunological ART eligibility 
criteria
At baseline, 196 (53.5%) of 366 children were eligible for
ART on clinical grounds (WHO clinical stage III or IV) and
202 (55.2%) were eligible based on any of the age-specific
immunological criteria (CD4 percent, CD4 count or TLC).
Agreement between clinical and immunological eligibility
criteria was poor (κ = 0.26). One third (32.6%, 64/196) of
children eligible by clinical criteria were not eligible
according to immunological criteria and one third
(34.7%, 70/202) of children eligible on immunological
criteria were not eligible by clinical criteria. Agreement
between clinical and individual immunological criteria
was poor to fair, with κ coefficients of 0.29 for CD4 per-
cent, 0.20 for CD4 count and 0.08 for TLC.
Evaluation of immunological criteria
Among children presenting with clinical stage I and II (i.e.
ineligible for ART based on clinical criteria), 54/170
(31.8%) were ART eligible by age-specific CD4 percent,
24/170 (14.1%) were ART eligible by age-specific CD4
count and 20/125 (16%) by TLC criteria. Overall, the
agreement between CD4 percent and CD4 count thresh-
olds was fair (κ = 0.39), the agreement between CD4 per-
cent and TLC was poor (κ = 0.04) (Table 3). Similar poor
to fair agreements were observed across age groups (Table
3). Among children presenting with clinical stage I and II
and eligible using CD4 percent thresholds measured by
flow cytometry, only 7/38 (18.4%) children age 0 to 8
years would have been eligible using the TLC threshold
and one in three (20/54 or 37.0%) children aged 0 to 12
years would have been eligible using CD4 count.
Evaluation of the CD4 percent computational estimate
The CD4 percent computational estimate was deemed
biologically plausible in the majority (99%, n = 362) of
children. In the remaining 1% (n = 4), the calculated CD4
percent was higher than 70%, a value rarely, if ever,
observed in vivo, and possibly due to discrepant lym-
phocyte count obtained by staining and flow cytometry.
Excluding the four values deemed implausible, the differ-
ence between the computational estimates and CD4 per-
cent obtained by flow cytometry was largest for children
with relatively high CD4 percent, and increased by 1.15%
(95%CI 1.11 to 1.18, p < 0.01, r2 = 0.91) for every percent
increase in CD4 percent obtained by flow cytometry (Fig-
ure 1).
Among children presenting in clinical stage I or II, a simi-
lar proportion of children was eligible using the two dif-
ferent CD4 percent methods: 52 (31.3%) using CD4
percent obtained by flow cytometry and 53 (31.9%) using
CD4 percent computational estimate (p = 0.9). The agree-
ment between results of computational estimates, includ-
ing those values deemed implausible, and CD4 percent
obtained by flow cytometry was good (κ = 0.71) except for
children age 35 to 59 months (Table 3).
In asymptomatic children, combining the CD4 computa-
tional estimate and CD4 count obtained with flow cytom-
Table 2: Median (Interquartile range, IQR) CD4 percent, CD4 count obtained by flow cytometry and total lymphocyte count by age 
group.
Age n CD4 percent CD4 count (cells/mm3) Total Lymphocyte Count (cells/mm3)
< 12 m 53 31 (21 to 35) 2144 (1716 to 2822) 6232 (4752 to 9112)
12–35 m 68 15 (12 to 22) 1030 (600 to 1459) 5839 (3650 to 8582)
36–59 m 60 13 (9 to 22) 600 (282 to 867) 3619 (2528 to 4925)
5–8 years 91 17 (9 to 25) 470 (329 to 818) 2976 (1875 to 4100)
> 8 years 95 17 (9 to 22) 415 (189 to 626) 2200 (1485 to 3162)BMC Infectious Diseases 2008, 8:31 http://www.biomedcentral.com/1471-2334/8/31
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etry would identify 2 extra children eligible for ART
treatment.
Cross-sectional baseline CD4 count, CD4 percent and TLC 
by age
Among children aged 5 to 12 years (n = 186), baseline
CD4 count was significantly higher in younger children (-
32 cells/mm3 per year, 95%CI -58 to -5, p = 0.02). Simi-
larly, a decrease in TLC was noted with increase in age (-
198 cells/mm3 per year, 95%CI -335 to -61, p < 0.01). In
contrast, CD4 percent obtained by flow cytometry at (-
0.8% per year (95%CI -0.73 to 0.57, p = 0.8) and compu-
tational estimate percent (-0.01%, 95%CI -0.97 to 0.77, p
= 0.9) remained stable (Figure 2).
Discussion
Performance of the clinical criteria
Similar to experiences in Uganda and Haiti, approxi-
mately half of the children in our DRC cohort were eligi-
ble for ART at first presentation, likely due to late care-
seeking and the recent introduction of free ART in these
settings [9,10].
The agreement between the WHO clinical stages and
immunological thresholds for ART eligibility was fair for
CD4 percent but poor for total CD4 count and TLC.
Approximately one third of children eligible for ART using
immunological criteria were not eligible using clinical cri-
teria. ART eligibility decision making on clinical grounds
only would thus delay ART initiation in these children
until they become symptomatic. Delay in ART initiation
could lead to death in young infants who progress rapidly.
Delayed ART initiation also impacts negatively immuno-
logical recovery following ART initiation, as patients with
a low CD4 lymphocyte nadir have a slower increases in
CD4 count, prolonging the period at risk of opportunistic
infections [11]. Furthermore, when ART is started in chil-
dren with less than 5% CD4 percent, levels of CD4 rarely
reach normal levels [12].
Up to 30% of symptomatic children (WHO clinical stage
III or IV) were not eligible for ART using immunological
criteria. Children in Sub Saharan Africa are exposed to
more infectious agents compared to children in industri-
alized countries. The high incidence of tuberculosis, bac-
terial dysentery, recurrent pneumonia and malnutrition
may have resulted in a high proportion of children classi-
fied in WHO stages III/IV despite a relatively good
immune system. Consequently, some children classified
as clinical WHO stage III/IV could start ART "too early", if
their symptoms are not the consequence of immunosup-
pression, but rather the result of environmental exposure.
This was also observed in Tanzania by Johnson et al, who
reported a sensitivity of 72% and a specificity of 56% of
WHO clinical stage III/IV to detect severe immunosup-
pression in HIV positive children and has also been
observed in adult populations [13,14]. In Cambodia, the
2003 WHO clinical criteria had a sensitivity of 96%, but
an equally low specificity of 57% to identify patients in
need of ART [14].
Because CD4 count and percentage only assess the level of
immune suppression in a quantitative manner, not quali-
tatively, it would be imprudent to delay ART in children
eligible based on clinical criteria. Results of the 3Cs4Kids
a meta-analysis untreated HIV infected children in
resource poor settings, showed that malnutrition, hemo-
globin and WHO stage III or IV disease, are associated
with high mortality independent of CD4 percentage or
count, underscoring that ART should not be delayed in
children with these conditions [15].
Performance of the immunological criteria
Understanding the correlations between CD4 count, TLC,
and CD4 percent is important in settings where access to
the gold standard CD4 percent assay is limited. In our
study, agreement between CD4 percent and total CD4
count or TLC was poor. Among children presenting in
clinical stage I and II, only one third of children eligible
according to CD4 percent criteria were eligible using total
CD4 count, and only one in five children eligible based
on CD4 percent were eligible according to TLC criteria.
The CD4 percent computational estimate correlated better
with the CD4 percent obtained by flow cytometry. More
Table 3: Agreement (κ coefficient) using CD4 count obtained by flow cytometry, CD4 percent by computational estimate, and total 
lymphocyte count (TLC) compared to CD4 percent obtained by flow cytometry for children not eligible for ART on clinical grounds, 
i.e. WHO stage I or II
Age group n CD4 count CD4 percent computational estimate TLC
Overall 170/125* 77.6% (0.39) 87.6% (0.71) 64.8% (0.04)*
≤ 11 months 41 78.0% (0.19) 87.8% (0.63) 80.5% (0.32)
12 to 35 months 22 68.2% (0.32) 95.4% (0.91) 54.5% (0.02)
36 to 59 months 21 71.4% (0.25) 71.4% (0.35) 47.6% (-0.32)
60 months to 96 months 41 85.4% (0.58) 92.7% (0.82) 63.4% (0.04)
≥ 96 months 45 77.8% (0.45) 86.7% (0.71) N/A†
* 125 children aged between 0 and 8 years; † Total lymphocyte count (TLC) is not valid in children older than 8 years (n = 45)BMC Infectious Diseases 2008, 8:31 http://www.biomedcentral.com/1471-2334/8/31
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than 80% of ART children eligible according to the CD4
percent obtained by flow cytometry were also eligible
using CD4 percent computational estimate. Use of the
CD4 percent computational estimate could thus represent
a substantial improvement compared to CD4 count.
Moreover, it is an easy method, which can be imple-
CD4 percent obtained by flow cytometry and computational estimate by age group: (A) 0 to 11 months, (B) 12 to 35 months,  (C) 36 to 59 months, (D) 60 to 95 months (E) more than 95 months Figure 1
CD4 percent obtained by flow cytometry and computational estimate by age group: (A) 0 to 11 months, (B) 12 
to 35 months, (C) 36 to 59 months, (D) 60 to 95 months (E) more than 95 months. Grey areas indicate children 
misclassified using CD4 percent computational estimate compared to CD4 percent obtained by flow cytometry.BMC Infectious Diseases 2008, 8:31 http://www.biomedcentral.com/1471-2334/8/31
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mented with limited extra cost beyond the cost of CD4
count, i.e. the cost to determine the total white blood cell
count and lymphocyte percentage. Furthermore, the use
of the CD4 percent computational estimate could facili-
tate decentralization of pediatric ART in centers without
the access to flow cytometry, which may result in
decreased indirect costs such as time off work and trans-
portation cost.
Because a smaller proportion of children is eligible
according to CD4 count compared to CD4 percent, rely-
ing on CD4 count for ART eligibility screening could delay
ART initiation in up to 30% of children, exposing them to
prolonged risk of acquiring opportunistic infections, dis-
ease progression or death. As the current WHO criteria are
based on US en European data, the underestimation of
children eligible for ART based on immunological criteria
may be even more pronounced in sub-Saharan African
settings, as genetic and environmental factors, which may
influence immunity, are currently not taken into account
in the WHO classification [15,16].
Decline of CD4 count in children older than 5 years
WHO recommends the use of total CD4 count for ART eli-
gibility screening in children older than 5 years. Similar to
findings in Ugandan and Kenyan HIV negative children
[5,6], CD4 count in HIV infected children in our study
continued to decrease between the ages of 5 and 12 years.
In contrast, both the CD4 percents measured by flow
cytometry and the computational estimates were stable
across age groups. Using CD4 count alone from the age of
5 might thus underestimate the number of children eligi-
ble for ART.
Study Limitations
Several limitations to this study should be noted. To cal-
culate the CD4 percent using the simple formula, we used
the CD4 count as determined by flow cytometry, and
although the lymphocytes were determined using an
automated complete blood count (CBC) method using
staining methods and not flow cytometry, the technique
used is also automated and may be too costly in many set-
tings. While others have demonstrated that low cost CD4
assays correlate well with the FACSCalibur assay [17,18],
the use of the CD4 count obtained by flow cytometry may
have resulted in an overestimation of the correlation of
Baseline total CD4 count and total lymphocyte count (TLC) decrease with increasing age (p < 0.01) Figure 2
Baseline total CD4 count and total lymphocyte count (TLC) decrease with increasing age (p < 0.01). CD4 per-
cent obtained by flow cytometryandcomputational estimate are stable with increasing age (p > 0.05). Linear prediction (and 
95%CI) of CD4 percent obtained by flow cytometry (solid line), CD4 percent computational estimate (dashed line), total CD4 
count (long dash line) and TLC (long dash – dotted line) in children aged 5 to 12 years.BMC Infectious Diseases 2008, 8:31 http://www.biomedcentral.com/1471-2334/8/31
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the CD4 percent computational estimates with the CD4
percent measured by flow cytometry. Prior to recom-
mending the use of this formula in resource poor settings,
the validity of this computational approach should there-
fore be evaluated using WBC count, percentage lym-
phocytes and CD4 count obtained through low cost (non
flow-based) assays. Second, the finding that baseline CD4
count and TLC decreased with increasing age was based
on cross sectional data analysis and not on longitudinal
follow up of children. The observed decrease could also be
due to increased immunosuppression with increasing age.
However, one would then also expect a decreasing CD4
percent with age, whereas our data demonstrated stable
CD4 percent values across the 5–12 years age group.
Lastly, the value of different ART eligibility criteria would
ideally be determined by their correlation with risk of
death or disease progression, as in cohort studies con-
ducted in European and USA in the early stage of the AIDS
epidemic. Clearly, in light of the effectiveness of and
increasing access to ART, such cohort studies can no
longer be performed. The 3Cs4Kids meta-analysis showed
that, compared to children in Europe and the US, children
in resource limited settings have a higher 12-month risk of
death at any level of CD4 percentage or count. However,
this study could not determine whether this increased risk
was attributable to immunosuppression or other factors,
such as the higher mortality seen in severely malnour-
ished children [15]. In contrast, trials, such as the CHER
and PREDICT trial, establishing the impact of early ART
initiation in children, might generate useful data on opti-
mal timing of ART [19,20].
Conclusion
CD4 percent is the most appropriate immunological crite-
rion to screen HIV infected children, aged 0 to 12 years,
for ART eligibility. CD4 percent will identify the highest
proportion of children at early stages of immunosuppres-
sion. CD4 count and TLC may be less appropriate as the
proposed WHO thresholds for total CD4 count and TLC
do not correspond well with CD4 percent, CD4 counts
decrease with increasing age, and using total CD4 count or
TLC underestimates the number of children eligible for
ART. Where access to CD4 percent assays is not available,
CD4 percent obtained with a simple formula based on
total white blood count, lymphocyte percent and total
CD4 count may improve the identification of children in
need of treatment in resource poor settings.
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